Cierra, Inc. obtient un financement de 21 millions de dollars aupr?s des meilleurs investisseurs en capital risque du secteur de la sant

Presse économique / Santé / Médical
BIOWIRE2K

REDWOOD CITY, Californie -- (BUSINESS WIRE) -- June 13, 2005 -- Cierra, Inc. a annoncé ce jour l’obtention d’un financement de 21 millions de dollars mené par la société de capital-risque Delphi Ventures, située à Menlo Park, en Californie. Ce tour de financement a également reçu un fort soutien de la part des investisseurs actuels, parmi lesquels figurent notamment Morgenthaler Ventures, Split Rock Ventures et Frazier Healthcare Ventures. Les fonds ainsi obtenus serviront principalement à entreprendre les essais cliniques puis à lancer la commercialisation de la technologie PFX™ de Cierra, une thérapie sans implant et à base de cathéter permettant de traiter les migraines grâce à la fermeture sans chirurgie cardiaque de la Persistance du Foramen Ovale (PFO), un défaut observé dans les chambres supérieures du cœur.

( BW)(CA-CIERRA) Cierra, Inc. Raises $21M from Top Venture Healthcare Investors

Business Editors/Health/Medical Writers BIOWIRE2K

REDWOOD CITY, Calif.--(BUSINESS WIRE)--June 13, 2005--Cierra, Inctoday announced a $21 million financing led by Delphi Ventures, Menlo Park, CA. The round also received strong support from current investors including Morgenthaler Ventures, Split Rock Ventures and Frazier Healthcare Ventures. The funds will be used primarily to launch US clinical trials and to initiate commercialization of Cierra's non-implant, catheter-based technology focused on migraine reduction by closure of Patent Foramen Ovale (PFO) in the heart

"Delphi Ventures is very pleased to lead this key round of financing for Cierra. Cierra has an outstanding team of professionals who have developed a unique approach to PFO closure that does not involve leaving behind an implant in the heart," said John Maroney a General Partner of Delphi Ventures

Erik Engelson, President and CEO of Cierra, said, "We are delighted both to have Delphi as an investor as well as by the continued broad support of the current investors." Delphi Ventures, based in Menlo Park, California, is a venture capital firm focused on early stage healthcare investing, including medical devices, diagnostics and biotechnology (www.delphiventures.com)

Headquartered in Redwood City, CA, Cierra, Inc. is a medical device company focused on minimally invasive treatment of heart conditions.

Cierra is the seventh portfolio company from the medical device incubator, The Foundry (www.the-foundry.com), and is privately held.

Venture investors in Cierra, Inc. include Morgenthaler Ventures (www.morgenthaler.com), Split Rock Partners (www.splitrockpartners.com) and Frazier Healthcare Ventures (www.frazierhealthcare.com).

CONTACT: Cierra, Inc

Erik T. Engelson, [email protected]

KEYWORD: CALIFORNIA

INDUSTRY KEYWORD: MEDICAL DEVICES PHARMACEUTICAL MEDICAL BIOTECHNOLOGY BANKING PRODUCT

SOURCE: Cierra, Inc.